Valuation: ANTS TECH

Market Cap 1.21B 846M 739M 684M 627M 1.19B 81.49B 8.15B 3.2B 39.91B 3.18B 3.11B 137B P/E 2026 *
-7.75x
P/E 2027 * -8.51x
Enterprise Value 1.21B 846M 739M 684M 627M 1.19B 81.49B 8.15B 3.2B 39.91B 3.18B 3.11B 137B EV / Sales 2026 *
87.2x
EV / Sales 2027 * 60.7x
Free-Float
83.53%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
-27.50%-17.14% - - 847M
+10.71%+3.83%-24.84%-8.43% 155B
+3.84%+1.89%-6.34%-4.67% 103B
+3.85%-0.51%+4.53%+60.90% 57.7B
-1.11%+4.77%+38.09%+52.37% 52.27B
+3.26%+6.22%-10.31%-38.34% 42.68B
+4.23%+2.01% - - 33.35B
+7.22%+5.29%-8.02%-43.21% 28.06B
+0.96%+2.48%+63.96%-5.89% 25.36B
-0.85%+8.07%-4.63%-18.66% 21.03B
Average -0.58%+0.23%+6.56%-0.74% 57.66B
Weighted average by Cap. +2.06%-1.71%-2.89%+2.20%

Financials

2026 *2027 *
Net sales 13.86M 9.7M 8.48M 7.84M 7.19M 13.62M 935M 93.49M 36.7M 458M 36.42M 35.63M 1.58B 19.93M 13.94M 12.18M 11.27M 10.34M 19.58M 1.34B 134M 52.75M 658M 52.35M 51.21M 2.26B
Net income -137M -95.83M -83.74M -77.48M -71.06M -135M -9.23B -924M -363M -4.52B -360M -352M -15.56B -154M -108M -94.34M -87.29M -80.07M -152M -10.4B -1.04B -408M -5.09B -405M -397M -17.53B
Net Debt - -
Logo ANTS TECH
Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company's ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-